INGELHEIM, Germany - Tuesday, December 22nd 2015 [ME NewsWire]
• The total investment is around a half billion euro.
• With this investment, Boehringer Ingelheim plans on adding more than 400 jobs.
• The biopharmaceutical production plant will go into operation by 2021.
(BUSINESS WIRE)--
Boehringer Ingelheim will make a significant investment in
biopharmaceutical production at its Vienna (Austria) site. There the
research-driven pharmaceutical company will establish a new large-scale
biopharmaceutical production facility for active ingredients
manufactured using cell cultures. With the roughly half billion euro
investment Boehringer Ingelheim will also create more than 400 new jobs
in the Austrian capital. The exact investment and job numbers will be
established as details are ironed out.
“This
is a decision for Europe as a pharma location,” said Professor Dr
Andreas Barner, Chairman of the Board of Managing Directors at
Boehringer Ingelheim. “We took a close look at various international
options as part of the investment decision, also considering the
research environment at potential sites. The clincher for Vienna was
ultimately the company’s desire to additionally secure the market supply
of biopharmaceutical products and to balance the risk by establishing a
further independent facility.”
In
Vienna, Boehringer Ingelheim has up to now produced pharmaceutical
active ingredients using microorganisms; over the next few years, cell
culture technology will also be transferred there. At the Biberach site,
two large-scale facilities for the market launch and cell culture based
manufacture of biopharmaceuticals have already been operating
successfully for many years. Biberach will remain Boehringer Ingelheim’s
largest European cell culture and global launch site for
biopharmaceutical products.
“Our
own promising biopharmaceutical development projects and the heavy
market demand for contract manufacturing were the basis for our decision
to invest long-term in our biopharmaceuticals activities to this
extent,” explained Dr Wolfgang Baiker, member of the Board of Managing
Directors responsible for biopharmaceuticals and operations. The
investment will strengthen Boehringer Ingelheim’s international
biopharmaceutical network and enhance its leading position in the
market. The new production plant will go into operation by 2021.
Boehringer
Ingelheim is one of the world’s largest manufacturers of
biopharmaceutical medicines. With over 35 years of experience, the
company is an industry pioneer and has manufactured more than 25
biopharmaceutical products for patients worldwide.
Boehringer Ingelheim
The
Boehringer Ingelheim group is one of the world’s 20 leading
pharmaceutical companies. Headquartered in Ingelheim, Germany,
Boehringer Ingelheim operates globally with 146 affiliates and a total
of more than 47,700 employees. The focus of the family-owned company,
founded in 1885, is researching, developing, manufacturing and marketing
new medications of high therapeutic value for human and veterinary
medicine.
Social
responsibility is an important element of the corporate culture at
Boehringer Ingelheim. This includes worldwide involvement in social
projects, such as the initiative “Making more Health” and caring for the
employees. Respect, equal opportunities and reconciling career and
family form the foundation of the mutual cooperation. In everything it
does, the company focuses on environmental protection and
sustainability.
In
2014, Boehringer Ingelheim achieved net sales of about 13.3 billion
euros. R&D expenditure corresponds to 19.9 per cent of its net
sales.
For more information please visit www.boehringer-ingelheim.com
Contacts
Boehringer Ingelheim
Corporate Communications
Media + PR
Dr. Ralph Warsinsky
Phone: +49 (6132) 77-7051
Fax: +49 6132–77-6601
Permalink: http://me-newswire.net/news/16690/en
No comments:
Post a Comment